Terry Kohler - 16 Jul 2026 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Reporting relationship: CFO and Treasurer
Issuer ticker: ADMA
Reported as of: 16 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 21:00:20 UTC
Prior SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Terry Kohler, by Michael A. Goldstein as Attorney-in-fact

Key filing fact

Terry Kohler filed Form 4 for ADMA BIOLOGICS, INC. (ADMA) on 17 Jul 2026.

Key facts

This page summarizes Terry Kohler's Form 4 filing for ADMA BIOLOGICS, INC. (ADMA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jul 2026, 21:00.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001872285 Primary reporting owner

Kohler Terry

Relationship: CFO and Treasurer
Address: C/O ADMA BIOLOGICS, INC., 5800 PARK OF COMMERCE BLVD. NW, BOCA RATON
Signature: /s/ Terry Kohler, by Michael A. Goldstein as Attorney-in-fact
Signature date: 17 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADMA transaction

Common Stock

Award

Transaction value
Shares: +85,130
Change %: +147%
Price: $0.000000^*
Shares after: 143,149
Date: 16 Jul 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADMA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +136,363
Change %
Price: $0.000000^*
Shares after: 136,363
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 136,363
Exercise price: $8.81
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Footnote F2

Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Footnote F3

This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date.